Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies
Phase 1 Completed
100 enrolled
TraveraRTGx
Completed
72 enrolled
IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC
Phase 2 Completed
63 enrolled 18 charts
TQB2618 Injection Combined With Penpulimab Injection in the Treatment of Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma
Phase 2 Completed
47 enrolled
A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010) (KEYNOTE-010)
Phase 3 Completed
511 enrolled 20 charts
Study of DF6215 in Patients With Advanced Solid Tumors
Phase 1 Completed
35 enrolled
Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors
Phase 2 Completed
161 enrolled
MK-4700-001
Phase 1 Completed
5 enrolled
A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010/LEAP-010)-China Extension
Phase 3 Completed
112 enrolled 16 charts
A Study to Evaluate the Safety and Efficacy of Lenvatinib in Participants With Refractory Differentiated Thyroid Cancer
Phase 4 Completed
50 enrolled
A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations
Phase 2 Completed
20 enrolled
A Phase I Comparative Study of Pharmacokinetics, Safety, and Efficacy of RPH-002 and Erbitux® in Unresectable Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma
Phase 1 Completed
118 enrolled
Study to Assess MEDI4736 With Either AZD9150 or AZD5069 in Advanced Solid Tumors & Relapsed Metastatic Squamous Cell Carcinoma of Head & Neck
Phase 1/2 Completed
340 enrolled 53 charts
MAGE-A10ᶜ⁷⁹⁶T for Urothelial Cancer, Melanoma or Head and Neck Cancers
Phase 1 Completed
10 enrolled
KEYNOTE-412
Phase 3 Completed
804 enrolled 20 charts
FORTITUDE-301
Phase 1/2 Completed
260 enrolled
A Study Evaluating Different Doses of BI 765049 When Given Alone and When Given With Ezabenlimab to Patients With Advanced Solid Tumors Expressing the Protein B7-H6 on the Cell Surface
Phase 1 Completed
67 enrolled
Dose-finding Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SNB-101(SN-38) in Patients With Tumors
Phase 1 Completed
21 enrolled
A Phase 1 Study in Patients With HPV16+ Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma
Phase 1 Completed
80 enrolled
LUX-Head&Neck 3: Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy
Phase 3 Completed
340 enrolled 23 charts
CONFIGURE
Phase NA Completed
41 enrolled 6 charts
Validation of Molecular Diagnostic Assays to Detect Cancer Biomarkers in Blood and Primary Tumor in HNSCC/NSCLC/Melanoma
Completed
135 enrolled
A First-in-Human, Phase 1 Study of JAB-3312 in Adult Patients With Advanced Solid Tumors
Phase 1 Completed
40 enrolled
Combination Trial of Tipifarnib and Alpelisib in Adult Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)
Phase 1/2 Completed
45 enrolled
A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQ®) in Patients With Ovarian Cancer and Selected Solid Tumors
Phase 2 Completed
25 enrolled 11 charts
Clinical Study of AL2846 Capsule in the Treatment of Differentiated Thyroid Cancer
Phase 1/2 Completed
33 enrolled
A Study of SGN-B6A in Chinese Participants With Advanced Solid Tumors
Phase 1 Completed
6 enrolled
TACTI-003
Phase 2 Completed
171 enrolled
LEAP-009
Phase 2 Completed
408 enrolled 17 charts
Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)
Phase 3 Completed
89 enrolled 14 charts
Retreatment With Intratumoral Diffusing Alpha Radiation Emitters
Phase NA Completed
2 enrolled
BURAN
Phase 3 Completed
487 enrolled
NAVIGATE
Phase 2 Completed
215 enrolled 5 FDA
Study of INCA32459 a LAG-3 and PD-1 Bispecific Antibody in Participants With Select Advanced Malignancies
Phase 1 Completed
46 enrolled
MK-1454-002
Phase 2 Completed
18 enrolled 14 charts
Study of DF9001 in Patients With Advanced Solid Tumors
Phase 1/2 Completed
24 enrolled
SYMTECH01
Completed
33 enrolled
To Compare The Effects Of Two Doses Of Vandetanib In Patients With Advanced Medullary Thyroid Cancer
Phase 4 Completed
81 enrolled 15 charts
Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid Tumors
Phase 1 Completed
204 enrolled
VERSATILE002
Phase 2 Completed
95 enrolled
SKYSCRAPER-09
Phase 2 Completed
123 enrolled
A Phase 2 Open Label Study of BA3021 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Phase 2 Completed
42 enrolled
First In Human Study With ABBV-CLS-579 When Given Alone and In Combination In Participants With Locally Advanced Or Metastatic Tumors
Phase 1 Completed
101 enrolled
An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer
Phase 3 Completed
331 enrolled 15 charts
A Phase 1/2 Study in Patients With HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Other Cancers
Phase 1/2 Completed
198 enrolled
A Study Evaluating Efficacy and Safety of Multiple Treatment Combinations in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck (Morpheus-Head and Neck Cancer)
Phase 1/2 Completed
12 enrolled 18 charts
Phase 1a/1b Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid Tumors
Phase 1 Completed
89 enrolled
Real-world Study of First Line Pembrolizumab- or Nivolumab-treated HPV-positive Recurrent/Metastatic Oropharyngeal Squamous Cell Carcinoma
Completed
662 enrolled
A Study of TAK-676 With Pembrolizumab After Radiation Therapy to Treat a Number of Cancers
Phase 1 Completed
34 enrolled 28 charts
A Study of Setanaxib Co-Administered With Pembrolizumab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN)
Phase 2 Completed
55 enrolled 32 charts